Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study

The PROSPECT study, a post-approval observational study in the U.S., showed no significant changes in lung function as measured by spirometry with clinical initiation of lumacaftor/ivacaftor. A sub-study within the PROSPECT study assessed the lung clearance index (LCI), as measured by multiple breath washout (MBW), a measure of lung function demonstrated to be sensitive among people with normal spirometry. Participants performed MBW prior to clinically initiating lumacaftor/ivacaftor therapy and for one year of follow-up.

Source: Journal of Cystic Fibrosis - June 5, 2020 Category: Respiratory Medicine Authors: Michelle Shaw, Umer Khan, John P. Clancy, Scott H. Donaldson, Scott D. Sagel, Steven M. Rowe, Felix Ratjen, PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network Tags: Short Communication Source Type: research